Daniel Mikol MD, PhD
Login to view DISC.Daniel Mikol is the Vice President of Neuroscience Development at AbbVie, leveraging his extensive experience in all phases of clinical development. A graduate of The University of Chicago Pritzker School of Medicine, he has a track record of successful drug approvals, including leading development for major therapies at Amgen and Biogen.
He previously served as Chief Medical Officer at NervGen Pharma, overseeing a Phase 1 trial for a molecule targeting spinal cord injury, and as Therapeutic Area Head for Neuroscience at Amgen.
He led the global clinical development for Aimovig (Erenumab), a transformative CGRP-inhibitor drug for migraine prevention, during his time at Amgen.
Read the full overview →How Daniel shows up
Behavioral traits and communication patterns that shape how this person evaluates opportunities, builds trust, and makes decisions in professional settings.
Topics Daniel cares about
Work history
Media appearances
DISC profile (public)
DISC behavioral profile
Dominance, influence, steadiness, and calculativeness scores with guidance on how this person prefers to communicate and decide.
Other AbbVie Employees
Explore more public profiles from related professionals.
More profiles
Discover additional public profiles from our index.
Search more profiles
Looking for someone else? Search here for anyone.